• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸膜间皮瘤的治疗:美国临床肿瘤学会指南更新

Treatment of Pleural Mesothelioma: ASCO Guideline Update.

作者信息

Kindler Hedy L, Ismaila Nofisat, Bazhenova Lyudmila, Chu Quincy, Churpek Jane E, Dagogo-Jack Ibiayi, Bryan Darren S, Drazer Michael W, Forde Patrick, Husain Aliya N, Sauter Jennifer L, Rusch Valerie, Bradbury Penelope A, Cho B C John, de Perrot Marc, Ghafoor Azam, Graham David L, Khorshid Ola, Lebensohn Alexandra, White Julie, Hassan Raffit

机构信息

University of Chicago Medicine, Chicago, IL.

American Society of Clinical Oncology, Alexandria, VA.

出版信息

J Clin Oncol. 2025 Mar 10;43(8):1006-1038. doi: 10.1200/JCO-24-02425. Epub 2025 Jan 8.

DOI:10.1200/JCO-24-02425
PMID:39778125
Abstract

PURPOSE

To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).

METHODS

ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

RESULTS

The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.

RECOMMENDATIONS

Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

摘要

目的

为执业医师及其他人员提供关于胸膜间皮瘤(PM)管理的循证建议。

方法

美国临床肿瘤学会召集了一个由医学肿瘤学、胸外科、放射肿瘤学、病理学、癌症遗传学及宣传专家组成的专家小组,进行最新文献检索,其中包括2016年至2024年发表的系统评价、荟萃分析、随机对照试验以及前瞻性和回顾性比较观察性研究。感兴趣的结果包括生存率、无病或无复发生存率以及生活质量。专家小组成员利用现有证据和非正式共识制定循证指南建议。

结果

文献检索确定了另外110项相关研究,为该指南的证据基础提供信息。

建议

针对PM患者的手术细胞减灭术、免疫治疗、化疗、病理学和种系检测制定了循证建议。更多信息可在www.asco.org/thoracic-cancer-guidelines获取。

相似文献

1
Treatment of Pleural Mesothelioma: ASCO Guideline Update.胸膜间皮瘤的治疗:美国临床肿瘤学会指南更新
J Clin Oncol. 2025 Mar 10;43(8):1006-1038. doi: 10.1200/JCO-24-02425. Epub 2025 Jan 8.
2
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.恶性胸膜间皮瘤的治疗:美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.
3
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.III 期非小细胞肺癌的管理:ASCO 指南。
J Clin Oncol. 2022 Apr 20;40(12):1356-1384. doi: 10.1200/JCO.21.02528. Epub 2021 Dec 22.
4
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.免疫治疗和生物标志物检测在复发性和转移性头颈部癌症中的应用:ASCO 指南。
J Clin Oncol. 2023 Feb 10;41(5):1132-1146. doi: 10.1200/JCO.22.02328. Epub 2022 Dec 15.
5
Management of Salivary Gland Malignancy: ASCO Guideline.唾液腺癌的治疗管理:ASCO 指南。
J Clin Oncol. 2021 Jun 10;39(17):1909-1941. doi: 10.1200/JCO.21.00449. Epub 2021 Apr 26.
6
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.小细胞肺癌的系统治疗:ASCO-安大略省健康(安大略省癌症护理)指南。
J Clin Oncol. 2023 Dec 10;41(35):5448-5472. doi: 10.1200/JCO.23.01435. Epub 2023 Oct 11.
7
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.恶性胸膜间皮瘤:调查、诊断与治疗的最新进展
Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016.
8
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.恶性胸膜间皮瘤:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Feb;33(2):129-142. doi: 10.1016/j.annonc.2021.11.005. Epub 2021 Nov 30.
9
Updates in the diagnosis and treatment of malignant pleural mesothelioma.恶性胸膜间皮瘤的诊断和治疗进展。
Curr Opin Pulm Med. 2018 Jul;24(4):319-326. doi: 10.1097/MCP.0000000000000489.
10
Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.口腔和口咽鳞状细胞癌颈部管理:ASCO 临床实践指南。
J Clin Oncol. 2019 Jul 10;37(20):1753-1774. doi: 10.1200/JCO.18.01921. Epub 2019 Feb 27.

引用本文的文献

1
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.可切除性弥漫性胸膜间皮瘤围手术期使用纳武利尤单抗或纳武利尤单抗联合伊匹木单抗:一项2期试验及循环肿瘤DNA分析
Nat Med. 2025 Sep 8. doi: 10.1038/s41591-025-03958-3.
2
Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.胸膜间皮瘤患者和曾经接触过石棉的工人对致癌性默克尔细胞多瘤病毒的免疫反应较差。
Transl Lung Cancer Res. 2025 Jul 31;14(7):2611-2625. doi: 10.21037/tlcr-2025-198. Epub 2025 Jul 28.
3
Pleural mesothelioma.
胸膜间皮瘤
Nat Rev Dis Primers. 2025 Aug 7;11(1):56. doi: 10.1038/s41572-025-00640-3.
4
Detecting likely germline variants during tumor-based molecular profiling.在基于肿瘤的分子谱分析过程中检测可能的种系变异。
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI190264.
5
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.化疗在胸膜恶性肿瘤治疗中的角色演变:当前证据与未来方向
Cancers (Basel). 2025 Jun 25;17(13):2143. doi: 10.3390/cancers17132143.
6
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives.BAP1突变与胸膜间皮瘤:遗传学见解、临床意义及治疗前景
Cancers (Basel). 2025 May 6;17(9):1581. doi: 10.3390/cancers17091581.
7
Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.肿瘤电场(TTFields)疗法治疗不可切除的胸膜间皮瘤:疗效、安全性及未来展望概述
Curr Treat Options Oncol. 2025 May;26(5):398-414. doi: 10.1007/s11864-025-01320-w. Epub 2025 Apr 23.
8
Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery.为何MARS2试验并不意味着所有间皮瘤手术的终结。
Cancers (Basel). 2025 Feb 21;17(5):724. doi: 10.3390/cancers17050724.
9
A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials.不可切除性胸膜间皮瘤一线治疗的Meta分析:来自六项随机对照试验的个体患者数据重建的间接比较
Cancers (Basel). 2025 Feb 3;17(3):503. doi: 10.3390/cancers17030503.